IQVIA (NYSE:IQV) Hits New 52-Week High – What’s Next?

IQVIA Holdings Inc. (NYSE:IQV) shares hit a new 52-week high on Monday . The stock traded as high as $234.50 and last traded at $234.5510, with a volume of 1012163 shares traded. The stock had previously closed at $225.37.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on the stock. Truist Financial reissued a “buy” rating and issued a $265.00 price objective (up from $235.00) on shares of IQVIA in a research note on Wednesday, October 29th. Weiss Ratings reiterated a “hold (c)” rating on shares of IQVIA in a research report on Wednesday, October 8th. UBS Group boosted their price objective on IQVIA from $225.00 to $250.00 and gave the stock a “buy” rating in a research note on Wednesday, October 29th. Jefferies Financial Group raised IQVIA from a “hold” rating to a “buy” rating and raised their price objective for the company from $195.00 to $225.00 in a research note on Tuesday, September 9th. Finally, TD Cowen downgraded IQVIA from a “buy” rating to a “hold” rating and boosted their target price for the company from $206.00 to $215.00 in a research report on Monday, November 3rd. Two equities research analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and six have assigned a Hold rating to the company’s stock. According to MarketBeat, IQVIA presently has an average rating of “Moderate Buy” and an average price target of $243.19.

IQVIA Stock Performance

The company has a quick ratio of 0.70, a current ratio of 0.70 and a debt-to-equity ratio of 2.03. The business has a 50 day moving average price of $222.34 and a 200 day moving average price of $198.36. The stock has a market cap of $39.93 billion, a P/E ratio of 32.17, a PEG ratio of 2.29 and a beta of 1.36.

IQVIA (NYSE:IQV) last posted its quarterly earnings data on Tuesday, October 28th. The medical research company reported $3.00 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.98 by $0.02. IQVIA had a return on equity of 30.70% and a net margin of 8.07%.The company had revenue of $4.10 billion during the quarter, compared to analysts’ expectations of $4.07 billion. During the same quarter in the previous year, the business earned $2.84 EPS. IQVIA’s revenue was up 5.2% compared to the same quarter last year. IQVIA has set its FY 2025 guidance at 11.850-11.950 EPS. As a group, sell-side analysts expect that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

Insider Buying and Selling

In related news, insider Eric Sherbet sold 4,000 shares of IQVIA stock in a transaction dated Wednesday, October 29th. The shares were sold at an average price of $219.70, for a total transaction of $878,800.00. Following the completion of the sale, the insider owned 27,108 shares in the company, valued at $5,955,627.60. This trade represents a 12.86% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 1.60% of the stock is owned by corporate insiders.

Institutional Trading of IQVIA

Several institutional investors and hedge funds have recently modified their holdings of IQV. Physician Wealth Advisors Inc. grew its stake in IQVIA by 1,340.0% in the third quarter. Physician Wealth Advisors Inc. now owns 144 shares of the medical research company’s stock worth $27,000 after purchasing an additional 134 shares in the last quarter. Westside Investment Management Inc. lifted its holdings in shares of IQVIA by 219.6% in the 3rd quarter. Westside Investment Management Inc. now owns 147 shares of the medical research company’s stock worth $30,000 after buying an additional 101 shares during the period. Measured Wealth Private Client Group LLC bought a new position in shares of IQVIA during the 3rd quarter worth $30,000. Atlantic Union Bankshares Corp purchased a new position in shares of IQVIA during the third quarter valued at $36,000. Finally, Root Financial Partners LLC bought a new stake in shares of IQVIA in the third quarter valued at about $43,000. Institutional investors own 89.62% of the company’s stock.

IQVIA Company Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.